Evidence map›Paper›PMID 24803811›Full record

ArticleWorld journal of gastroenterology2014

Clinical and histopathological correlations of fecal calprotectin release in colorectal carcinoma.

Frank Serge Lehmann, Francesca Trapani, Ida Fueglistaler, Luigi Maria Terracciano, Markus von Flüe, Gieri Cathomas, Andreas Zettl, Pascal Benkert, Daniel Oertli, Christoph Beglinger

Abstract readMulticenter Study
In one paragraph

Article in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Diagnostic accuracy of fecal calprotectin for screening patients with colorectal cancer: A meta-analysis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2018
    Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Biomarkers in inflammatory bowel disease: a practical guide.Therapeutic advances in gastroenterology · 2024
    Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Role of S100 Proteins in Colorectal Carcinogenesis.Gastroenterology research and practice · 2016
    Review
  16. Review
  17. Serum calprotectin: a new potential biomarker for thyroid papillary carcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015
    Article
  18. The role and utility of faecal markers in inflammatory bowel disease.Therapeutic advances in gastroenterology · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Frank Serge LehmannFrank Serge Lehmann, Christoph Beglinger, Division of Gastroenterology and Hepatology, University Hospital, 4031 Basel, Switzerland.
Francesca TrapaniFrank Serge Lehmann, Christoph Beglinger, Division of Gastroenterology and Hepatology, University Hospital, 4031 Basel, Switzerland.
Ida FueglistalerFrank Serge Lehmann, Christoph Beglinger, Division of Gastroenterology and Hepatology, University Hospital, 4031 Basel, Switzerland.
Luigi Maria TerraccianoFrank Serge Lehmann, Christoph Beglinger, Division of Gastroenterology and Hepatology, University Hospital, 4031 Basel, Switzerland.
Markus von FlüeFrank Serge Lehmann, Christoph Beglinger, Division of Gastroenterology and Hepatology, University Hospital, 4031 Basel, Switzerland.
Gieri CathomasFrank Serge Lehmann, Christoph Beglinger, Division of Gastroenterology and Hepatology, University Hospital, 4031 Basel, Switzerland.
Andreas ZettlFrank Serge Lehmann, Christoph Beglinger, Division of Gastroenterology and Hepatology, University Hospital, 4031 Basel, Switzerland.
Pascal BenkertFrank Serge Lehmann, Christoph Beglinger, Division of Gastroenterology and Hepatology, University Hospital, 4031 Basel, Switzerland.
Daniel OertliFrank Serge Lehmann, Christoph Beglinger, Division of Gastroenterology and Hepatology, University Hospital, 4031 Basel, Switzerland.
Christoph BeglingerFrank Serge Lehmann, Christoph Beglinger, Division of Gastroenterology and Hepatology, University Hospital, 4031 Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo determine calprotectin release before and after colorectal cancer operation and compare it to tumor and histopathological parameters.

methodsThe study was performed on patients with diagnosed colorectal cancer admitted for operation. Calprotectin was measured in a single stool sample before and three months after the operation using an enzyme-linked immunosorbent assay (ELISA). Calprotectin levels greater than or equal to 50 μg/g were considered positive. The compliance for collecting stool samples was assessed and the value of calprotectin was correlated to tumor and histopathological parameters of intra- and peri-tumoral inflammation. Surgical specimens were fixed in neutral buffered formalin and stained with hematoxylin and eosin. Staging was performed according to the Dukes classification system and the 7(th) edition tumor node metastasis classification system. Intra- and peri-tumoral inflammation was graded according to the Klintrup criteria. Immunohistochemical quantification was performed for MPO, CD45R0, TIA-1, CD3, CD4, CD8, CD57, and granzyme B. Statistical significance was measured using Wilcoxon signed rank test, Kruskal Wallis test and Spearman's rank correlation coefficient as appropriate.

resultsBetween March 2009 and May 2011, 80 patients with colorectal cancer (46 men and 34 women, with mean age of 71 ± 11.7 years old) were enrolled in the study. Twenty-six patients had rectal carcinoma, 29 had left-side tumors, 23 had right-side tumors, and 2 had bilateral carcinoma. In total, 71.2% of the patients had increased levels of calprotectin before the operation (median 205 μg/g, range 50-2405 μg/g) and experienced a significant decrease three months after the operation (46 μg/g, range 10-384 μg/g, P < 0001). The compliance for collecting stool samples was 89.5%. Patients with T3 and T4 tumors had significantly higher values than those with T1 and T2 cancers (P = 0.022). For all other tumor parameters (N, M, G, L, V, Pn) and location, no significant difference in calprotectin concentration was found. Furthermore, the calprotectin levels and histological grading of both peri- and intra-tumoral inflammation was not correlated. Additional testing with specific markers for lymphocytes and neutrophils also revealed no statistically significant correlation.

conclusionFecal calprotectin decreases significantly after colorectal cancer operation. Its value depends exclusively on the individual T-stage, but not on other tumor or histopathological parameters.

Indexed as

AgedAged, 80 and overBiomarkers, TumorBiopsyCarcinomaColectomyColorectal NeoplasmsEnzyme-Linked Immunosorbent AssayFecesFemaleHumansImmunohistochemistryLeukocyte L1 Antigen ComplexMaleMiddle AgedNeoplasm StagingBiomarkers, TumorLeukocyte L1 Antigen ComplexCalprotectinColorectal cancerGranulocytesInflammationTumor size

Identifiers

PMID24803811
PMCPMC4009532

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.